|
Orthologous residues
|
|
CACNG2 (human): S237‑p, CACNG2 (mouse): S237‑p, CACNG2 (rat): S237‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
2D analysis, [32P] bio-synthetic labeling, electrophoretic mobility shift, mutation of modification site, phosphoamino acid analysis, phosphopeptide mapping
|
|
Relevant cell lines - cell types - tissues:
'brain, hippocampus', CHO (fibroblast), neuron-'brain, cerebral cortex', oocyte
|
|
Cellular systems studied:
cell lines, primary cells, primary cultured cells, tissue
|
|
Species studied:
frog, hamster, mouse
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
TTX
|
|
|
|
increase
|
|
|
APV
|
|
|
|
increase
|
|
|
tautomycin
|
|
|
|
increase
|
|
|
okadaic acid
|
|
|
|
increase
|
|
|
FK506
|
|
|
|
increase
|
|
|
NMDA
|
|
|
|
decrease
|
|
|
KN-93
|
NMDA
|
|
|
augment treatment-induced decrease
|
inhibits the recovery
|
|
GF109203X
|
NMDA
|
|
|
augment treatment-induced decrease
|
inhibits the recovery
|
|
PD98059
|
NMDA
|
|
|
no effect upon treatment-induced decrease
|
|
|
KT5720
|
NMDA
|
|
|
no effect upon treatment-induced decrease
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
activation
|
|
Comments:
enhances AMPA receptor responses and is required for long-term potentiation
|
|
|